InstaCare Updates 2011 Guidance for All Product Lines in Report Penned by William Walling, CFA

NEW YORK, Jan. 25, 2011 /PRNewswire/ -- InstaCare Corp. (OTC Bulletin Board: ISCR) a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and a leading developer of revolutionary cell phone centric e-health products and technologies, today announced that the company's Board of Directors has received the completed FY 2011 Guidance Report from Mr. William N. Walling, Jr., CFA.  This report covers 2011 guidance for the company's three business lines inclusive of its new Shasta Genstrip diagnostic product being sold exclusively through the company's Pharma Tech Solutions, Inc. subsidiary.  The entire report is currently available for viewing on the company's website www.instacare.net.

Mr. Walling, an expert financial analyst specializing in the domestic healthcare paradigm, was contracted to review the company's performance, its progress with project development, product pipeline advancement, new product introductions (Genstrip) and financial results. Mr. Walling's report includes an expectation of continued strength from current product offerings, and substantial industry traction developing around the Shasta Genstrip diagnostic product and its substantial revenue and margin contribution potential.

Mr. Walling commented, "InstaCare has been building a strategic presence in the diabetic market since 2008, which is a testimony to the savvy management of this company and its ability to overcome obstacles placed in their way. With other strategic initiatives that are brewing, it is conceivable that under-recognized ISCR could garner as much as 5% ($600 million) of the glucose-monitoring market in the U.S. in a few years."

Keith Berman, Secretary and CFO of InstaCare Corp. commented:  "Mr. Walling's complete report reinforces the company's goals to emerge as a marketing and distribution force in the ever growing diabetes marketplace.  This report should confirm the validity of the company's business model and the viability of our continued success, currently, recently and into the future."

For more information about InstaCare Corp., Pharma Tech Solutions, inc., the Genstrip and/or its revolutionary MD@Hand cell phone centric technologies, please visit the InstaCare web site www.instacare.net or call the company at (805) 446-2973.

Forward-Looking Statements:

Forward-looking statements are statements made herein which do not address historical facts and, therefore could be interpreted to be forward-looking statements.  We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions. All forward-looking statements are intended to be covered by the safe harbor created by Section 21E of the Securities Exchange Act of 1934.  Such statements are subject to factors that could cause actual results to differ materially from anticipated results. The forward-looking statements included in this press release represent our views as of January 11, 2011.  We anticipate that subsequent events and developments will cause our views to change.

SOURCE InstaCare Corp.